Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of alternate 2-dose Cecolin regimens in girls aged 9-14 years
PACTR202008675647876Phase 3Completed
- Sponsor
- PATH
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine and qHPV vaccine in human papillomavirus infection and Cervical Cancer (CC) (4 arms), sponsored by PATH. Primary endpoint: Anti-HPV 16 and 18 IgG geometric mean concentration. Started Dec 2020; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on PACTR202008675647876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202008675647876.